Syncona
Limited
Legal Entity
Identifier – 213800X8MBI5VQITLW60
Syncona appoints
Robert Hutchinson as Non-Executive
Director
16 October 2017
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, today announces
that Robert Hutchinson has been
appointed as Non-Executive Director of the Company, with effect
from 1 November 2017.
Mr Hutchinson brings many years of broad financial experience to
the role, having spent 28 years at KPMG. He was appointed partner
in 1999 and specialised in the audit of banking and fund
clients. He led the firm’s fund and private equity practices
for seven years and served as Head of Audit for KPMG in the
Channel Islands for five years
until 2013.
Mr Hutchinson retired from practice in 2014 and is a Fellow of
the Institute of Chartered Accountants in England and Wales. He served as President of the Guernsey
Society of Chartered and Certified Accountants between 2007 and
2009.
There is no information to be disclosed pursuant to LR 9.6.13R
in respect of Mr Hutchinson. As at the date of this
announcement, he has no beneficial interests in the ordinary shares
of the Company.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Notes to Editors
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior
returns by investing in long only and alternative investment funds.
This represents a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life
sciences as we target the best new opportunities and support our
existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.